LP-300 for Lung Adenocarcinoma

Phase-Based Progress Estimates
New York Cancer & Blood Specialists, Riverhead, NYLung Adenocarcinoma+1 MoreLP-300 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug combo to see if it's more effective than the current standard of care, in patients who have never smoked.

Eligible Conditions
  • Lung Adenocarcinoma
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Study Objectives

2 Primary · 3 Secondary · Reporting Duration: Through study completion, an average of 2 years

Year 2
Clinical benefit rate (CBR)
Duration of objective response (DOR)
Objective response rate (ORR)
Overall survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Pemetrexed and Carboplatin (Standard of Care)
1 of 2
LP-300 in Combination with Pemetrexed and Carboplatin
1 of 2

Active Control

Experimental Treatment

90 Total Participants · 2 Treatment Groups

Primary Treatment: LP-300 · No Placebo Group · Phase 2

LP-300 in Combination with Pemetrexed and CarboplatinExperimental Group · 3 Interventions: Carboplatin, LP-300, Pemetrexed · Intervention Types: Drug, Drug, Drug
Pemetrexed and Carboplatin (Standard of Care)ActiveComparator Group · 2 Interventions: Carboplatin, Pemetrexed · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 2 years

Who is running the clinical trial?

Lantern Pharma Inc.Lead Sponsor
1 Previous Clinical Trials
27 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 15 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have lung cancer that has spread and cannot be removed through surgery.
You have metastases in your brain and have not experienced any recent cognitive or physical issues related to the metastases. You have stopped taking seizure medication and steroids at least two weeks ago.

Frequently Asked Questions

Is this research endeavor taking on new participants presently?

"Data on clinicaltrials.gov indicates that recruitment for this medical trial is currently underway, with the initial posting being made on August 12th 2022 and most recent update occurring 16 days later." - Anonymous Online Contributor

Unverified Answer

How many individuals are being included as part of this research endeavor?

"Indeed, the information on clinicaltrials.gov confirms this trial is still recruiting candidates. It was first published on August 12th 2022 and revised most recently on September 16th 2022. The investigators are seeking 90 volunteers to participate in this study at two distinct sites." - Anonymous Online Contributor

Unverified Answer

Has the FDA authorized LP-300 as a treatment option?

"LP-300's safety rating stands at 2 due to the Phase 2 trial data, which has not yet shown efficacy but does offer evidence of its security." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.